publication . Article . 2015

Programmed cell death 6 interacting protein (PDCD6IP) and Rabenosyn‐5 (ZFYVE20) are potential urinary biomarkers for upper gastrointestinal cancer

Husi, Holger; Skipworth, Richard J.E.; Cronshaw, Andrew; Stephens, Nathan A.; Wackerhage, Henning; Greig, Carolyn; Fearon, Kenneth C.H.; Ross, James A.;
Open Access
  • Published: 01 Jun 2015 Journal: PROTEOMICS - Clinical Applications, volume 9, pages 586-596 (issn: 1862-8346, Copyright policy)
  • Publisher: Wiley
  • Country: India
Abstract
PURPOSE: \ud \ud Cancer of the upper digestive tract (uGI) is a major contributor to cancer-related death worldwide. Due to a rise in occurrence, together with poor survival rates and a lack of diagnostic or prognostic clinical assays, there is a clear need to establish molecular biomarkers.\ud \ud EXPERIMENTAL DESIGN: \ud \ud Initial assessment was performed on urine samples from 60 control and 60 uGI cancer patients using MS to establish a peak pattern or fingerprint model, which was validated by a further set of 59 samples.\ud \ud RESULTS: \ud \ud We detected 86 cluster peaks by MS above frequency and detection thresholds. Statistical testing and model buildi...
Subjects
free text keywords: Clinical Biochemistry, Cancer screening, Urine, Biology, Clinical significance, Cancer, medicine.disease, medicine, Blot, Bioinformatics, S100A9, S100A8, Biomarker (medicine)
67 references, page 1 of 5

1. Ferlay, J., Shin, H. R., Bray, F., Forman, D. et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 2010, 127 (12), 2893-2917.

2. Shahbaz Sarwar, C. M., Luketich, J. D., Landreneau, R. J., Abbas, G., Esophageal cancer: an update. Int. J. Surg. 2010, 8 (6), 417-422.

3. Zhang, Y., Epidemiology of esophageal cancer. World J. Gastroenterol. 2013, 19 (34), 5598-5606.

4. Gungor, C., Hofmann, B. T., Wolters-Eisfeld, G., Bockhorn, M., Pancreatic Cancer. Br. J. Pharmacol. 2013.

5. Hu, Q. D., Zhang, Q., Chen, W., Bai, X. L., Liang, T. B., Human development index is associated with mortality-to-incidence ratios of gastrointestinal cancers. World J. Gastroenterol. 2013, 19 (32), 5261-5270.

6. Rastogi, T., Devesa, S., Mangtani, P., Mathew, A. et al. Cancer incidence rates among South Asians in four geographic regions: India, Singapore, UK and US. Int. J. Epidemiol. 2008, 37 (1), 147-160.

7. Clemons, N., Phillips, W., Lord, R. V., Signaling pathways in the molecular pathogenesis of adenocarcinomas of the esophagus and gastresophageal junction. Cancer Biol. Ther. 2013, 14 (9).

8. Matsumoto, S., Takayama, T., Wakatsuki, K., Enomoto, K. et al. Predicting early cancer-related deaths after curative esophagectomy for esophageal cancer. Am. Surg. 2013, 79 (5), 528-533.

9. Taylor, M. D., LaPar, D. J., Davis, J. P., Isbell, J. M. et al. Induction chemoradiotherapy and surgery for esophageal cancer: survival benefit with downstaging. Ann. Thorac. Surg. 2013, 96 (1), 225-230.

10. Hennies, S., Hermann, R. M., Gaedcke, J., Grade, M. et al. Increasing toxicity during neoadjuvant radiochemotherapy as positive prognostic factor for patients with esophageal carcinoma. Dis. Esophagus. 2013. [OpenAIRE]

11. Fry, L. C., Monkemuller, K., Malfertheiner, P., Molecular markers of pancreatic cancer: development and clinical relevance. Langenbecks Arch. Surg. 2008, 393 (6), 883-890. [OpenAIRE]

12. Ballehaninna, U. K., Chamberlain, R. S., Serum CA 19-9 as a Biomarker for Pancreatic Cancer-A Comprehensive Review. Indian J. Surg. Oncol. 2011, 2 (2), 88-100.

13. Singh, S., Tang, S. J., Sreenarasimhaiah, J., Lara, L. F., Siddiqui, A., The clinical utility and limitations of serum carbohydrate antigen (CA19-9) as a diagnostic tool for pancreatic cancer and cholangiocarcinoma. Dig. Dis. Sci. 2011, 56 (8), 2491- 2496.

14. Kim, J. E., Lee, K. T., Lee, J. K., Paik, S. W. et al. Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population. J. Gastroenterol. Hepatol. 2004, 19 (2), 182-186.

15. Zhang, S., Wang, Y. M., Sun, C. D., Lu, Y., Wu, L. Q., Clinical value of serum CA19-9 levels in evaluating resectability of pancreatic carcinoma. World J. Gastroenterol. 2008, 14 (23), 3750-3753.

67 references, page 1 of 5
Related research
Abstract
PURPOSE: \ud \ud Cancer of the upper digestive tract (uGI) is a major contributor to cancer-related death worldwide. Due to a rise in occurrence, together with poor survival rates and a lack of diagnostic or prognostic clinical assays, there is a clear need to establish molecular biomarkers.\ud \ud EXPERIMENTAL DESIGN: \ud \ud Initial assessment was performed on urine samples from 60 control and 60 uGI cancer patients using MS to establish a peak pattern or fingerprint model, which was validated by a further set of 59 samples.\ud \ud RESULTS: \ud \ud We detected 86 cluster peaks by MS above frequency and detection thresholds. Statistical testing and model buildi...
Subjects
free text keywords: Clinical Biochemistry, Cancer screening, Urine, Biology, Clinical significance, Cancer, medicine.disease, medicine, Blot, Bioinformatics, S100A9, S100A8, Biomarker (medicine)
67 references, page 1 of 5

1. Ferlay, J., Shin, H. R., Bray, F., Forman, D. et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 2010, 127 (12), 2893-2917.

2. Shahbaz Sarwar, C. M., Luketich, J. D., Landreneau, R. J., Abbas, G., Esophageal cancer: an update. Int. J. Surg. 2010, 8 (6), 417-422.

3. Zhang, Y., Epidemiology of esophageal cancer. World J. Gastroenterol. 2013, 19 (34), 5598-5606.

4. Gungor, C., Hofmann, B. T., Wolters-Eisfeld, G., Bockhorn, M., Pancreatic Cancer. Br. J. Pharmacol. 2013.

5. Hu, Q. D., Zhang, Q., Chen, W., Bai, X. L., Liang, T. B., Human development index is associated with mortality-to-incidence ratios of gastrointestinal cancers. World J. Gastroenterol. 2013, 19 (32), 5261-5270.

6. Rastogi, T., Devesa, S., Mangtani, P., Mathew, A. et al. Cancer incidence rates among South Asians in four geographic regions: India, Singapore, UK and US. Int. J. Epidemiol. 2008, 37 (1), 147-160.

7. Clemons, N., Phillips, W., Lord, R. V., Signaling pathways in the molecular pathogenesis of adenocarcinomas of the esophagus and gastresophageal junction. Cancer Biol. Ther. 2013, 14 (9).

8. Matsumoto, S., Takayama, T., Wakatsuki, K., Enomoto, K. et al. Predicting early cancer-related deaths after curative esophagectomy for esophageal cancer. Am. Surg. 2013, 79 (5), 528-533.

9. Taylor, M. D., LaPar, D. J., Davis, J. P., Isbell, J. M. et al. Induction chemoradiotherapy and surgery for esophageal cancer: survival benefit with downstaging. Ann. Thorac. Surg. 2013, 96 (1), 225-230.

10. Hennies, S., Hermann, R. M., Gaedcke, J., Grade, M. et al. Increasing toxicity during neoadjuvant radiochemotherapy as positive prognostic factor for patients with esophageal carcinoma. Dis. Esophagus. 2013. [OpenAIRE]

11. Fry, L. C., Monkemuller, K., Malfertheiner, P., Molecular markers of pancreatic cancer: development and clinical relevance. Langenbecks Arch. Surg. 2008, 393 (6), 883-890. [OpenAIRE]

12. Ballehaninna, U. K., Chamberlain, R. S., Serum CA 19-9 as a Biomarker for Pancreatic Cancer-A Comprehensive Review. Indian J. Surg. Oncol. 2011, 2 (2), 88-100.

13. Singh, S., Tang, S. J., Sreenarasimhaiah, J., Lara, L. F., Siddiqui, A., The clinical utility and limitations of serum carbohydrate antigen (CA19-9) as a diagnostic tool for pancreatic cancer and cholangiocarcinoma. Dig. Dis. Sci. 2011, 56 (8), 2491- 2496.

14. Kim, J. E., Lee, K. T., Lee, J. K., Paik, S. W. et al. Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population. J. Gastroenterol. Hepatol. 2004, 19 (2), 182-186.

15. Zhang, S., Wang, Y. M., Sun, C. D., Lu, Y., Wu, L. Q., Clinical value of serum CA19-9 levels in evaluating resectability of pancreatic carcinoma. World J. Gastroenterol. 2008, 14 (23), 3750-3753.

67 references, page 1 of 5
Related research
Powered by OpenAIRE Research Graph
Any information missing or wrong?Report an Issue